Alumis (ALMS)
Develops oral TYK2 therapies for immune-mediated diseases in the body and brain.
Something off on this page? Send us feedback.
Develops oral TYK2 inhibitors for immune-mediated disease, led by late-stage envudeucitinib for plaque psoriasis and lupus, with A-005 targeting CNS disorders. Revenue currently comes from the Kaken collaboration rather than product sales, and Japanese dermatology rights for envudeucitinib are licensed to that partner.
Develops targeted therapies for immune-mediated diseases using precision data analytics and clinical development. Lead asset envudeucitinib is an oral TYK2 inhibitor being prepared for a plaque-psoriasis regulatory submission after pivotal trials, while a separate study evaluates it in systemic lupus erythematosus. A-005 is a CNS-penetrant TYK2 inhibitor being advanced toward a Parkinson's disease biomarker trial. Strategic alternatives are being explored for lonigutamab, an anti-IGF-1R antibody for thyroid eye disease acquired with ACELYRIN.
Operates without approved products or product-sales revenue, generating collaboration revenue through Kaken while funding research and trials. Clinical results, regulatory approval, commercialization readiness, outsourced manufacturing, and access to capital determine whether the pipeline can reach patients. Kaken holds exclusive Japanese rights to develop and commercialize envudeucitinib for dermatology, with options in certain other fields; Alumis retains rights elsewhere.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 3, 2026 | Guggenheim | Downgrade | ||
| Sep 2, 2026 | Oppenheimer | Reiterate | Rating: —Target: $50 | Target: $37 |
| Sep 2, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $39 | Target: $29 |
| Sep 2, 2026 | H.C. Wainwright | Upgrade | Target: $25 | Target: $15 |
| Sep 2, 2026 | HC Wainwright & Co. | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $502.3M · Total debt $36.4M · Total assets $560.6M · Shareholders' equity $452.2M
- Revenue
- $1.7M
- Operating income
- −$148.9M
- Net income
- −$142.2M
No dividends on record.
| Institutions | ≈ 90.91% | 117.67M shares | |
|---|---|---|---|
| 213 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.32% | 1.71M shares | |
| 15 holders · as of Sep 9, 2026 | |||
| Strategic holders | 0.53% | 680.5K shares | |
| 1 holder · as of Apr 3, 2026 | |||
| Other | ≈ 7.24% | 9.38M shares | |
| remainder | |||
129.44M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
AyurMaya Capital Management Company, LPInstitution | 11.70% | 15.14M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 6.35% | 8.22M | as of Jun 30, 2026 |
FMR LLCInstitution | 5.23% | 6.77M | as of Jun 30, 2026 |
Deep Track Capital, LPInstitution | 4.90% | 6.35M | as of Jun 30, 2026 |
Samsara Biocapital, LLCInstitution | 4.90% | 6.35M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 8, 2026 | Srinivas Akkaraju | director | +546,581 | $10.63 |
| Sep 8, 2026 | Srinivas Akkaraju | director | −96,131 | $10.55 |
| Sep 4, 2026 | Srinivas Akkaraju | director | +220,070 | $11.17 |
| Aug 3, 2026 | Mark Christopher Bradley | officer: Chief Development Officer | −2,572 | $26.37 |
| Aug 3, 2026 | Jorn Drappa | officer: Chief Medical Officer | −2,447 | $26.37 |
- Bristol-Myers Squibb
Same-mechanism TYK2 benchmark in psoriasis and SLE
- Takeda (ADR)
Next-generation oral TYK2 challenger in psoriasis
- Johnson & Johnson
Oral IL-23R psoriasis rival to TYK2 pills
- Amgen
Psoriasis oral comparator and TED incumbent
- AbbVie
Large immunology incumbent in psoriasis and SLE
- AstraZeneca (ADR)
Approved SLE biologic competing with lupus entry
- GSK (ADR)
Established lupus biologic benchmark
- Viridian Therapeutics
Late-stage TED anti-IGF-1R challenger
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Alumis | $7.38 | −9.00% | $1.00B | — | — | 135.3 | −37.7% |
| Bristol-Myers Squibb | $61.51 | −1.19% | $127.16B | 13.7 | 9.6 | 2.6 | +5.7% |
| Takeda (ADR) | $18.81 | −0.74% | $60.30B | 52.9 | 59.8 | 2.0 | +4.2% |
| Johnson & Johnson | $266.87 | −0.86% | $648.72B | 31.2 | 22.5 | 6.6 | +6.6% |
| Amgen | $406.78 | −0.84% | $221.41B | 25.5 | 17.3 | 5.8 | +9.7% |
| AbbVie | $264.50 | −0.27% | $468.77B | 74.8 | 17.4 | 7.3 | +10.2% |
| AstraZeneca (ADR) | $163.68 | −2.79% | $261.12B | 25.3 | 15.4 | 4.3 | +6.4% |
| GSK (ADR) | $49.81 | −1.79% | $101.62B | 16.1 | 9.2 | 2.3 | +5.3% |
| Viridian Therapeutics | $21.49 | −2.83% | $2.51B | — | — | 35.2 | +278.7% |
| Median | 25.5 | 17.3 | 5.0 | +6.5% |